Molbio Diagnostics share price
NSE: MOLBIOBSE: 544866Healthcare Equipment & Supplies
Molbio Diagnostics Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2026 · Issue price ₹807
Last close ₹1,274.00down ₹28.60 (2.20%)BSE ₹1,274.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,302.60.
30 Oct: open ₹1,315.00, high ₹1,345.00, low ₹1,262.60
Range of traded prices from listing on 17 Aug 2026 to 30 Oct 2026
₹926.35Low, 17 Aug 2026₹1,686.80High, 11 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹14,682 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No balance sheet
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Aug 2026
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,47,90716.7% delivered
Results
Consolidated; ₹ crore; no annual accounts on record yet.Molbio Diagnostics quarterly results
Quarter to Jun 2026
- Revenue
- ₹408 Cr
- Net profit
- ₹53 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.9%
| ₹ crore | Jun 2026 |
|---|---|
| Revenue | 408 |
| Net profit | 53 |
| Net margin | 12.9% |
Consolidated. The quarter to Jun 2026, the first on record. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the quarter to Jun 2026 the company reports one business segment, Healthcare, which carries all its revenue.
Mutual fund holdings
30 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.All 30 funds holding Molbio Diagnostics
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 8
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 2
| Fund | |||
|---|---|---|---|
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 27,50,000 | 0.54% | ₹359.9 Cr |
 HDFC Flexi Cap FundHDFC Mutual Fund | 23,00,000 | 0.28% | ₹301.0 Cr |
| Kotak Aggressive Hybrid FundKotak Mahindra Mutual Fund | 15,00,000 | 2.17% | ₹196.3 Cr |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 5,38,006 | 2.01% | ₹70.4 Cr |
| Kotak Contra FundKotak Mahindra Mutual Fund | 5,19,576 | 1.31% | ₹68.0 Cr |
 Mirae Asset Healthcare FundMirae Asset Mutual Fund | 4,72,842 | 1.77% | ₹61.9 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 3,80,293 | 0.54% | ₹49.8 Cr |
| Mirae Asset Flexi Cap FundMirae Asset Mutual Fund | 3,50,000 | 1.05% | ₹45.8 Cr |
| Kotak Large Cap FundKotak Mahindra Mutual Fund | 3,44,626 | 0.43% | ₹45.1 Cr |
| HDFC Value FundHDFC Mutual Fund | 3,33,622 | 0.54% | ₹43.7 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Molbio Diagnostics competitors and peers
Medical Equipment & Supplies, 27 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Molbio Diagnostics in market cap.Healthcare companies
Molbio Diagnostics is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Poly MedicurePOLYMED | 14,692 | 46.63 | 4.73 | +18.3% | −11.9% | 10.7% | 9.5% | 0.24% |
 Sahajanand Medical TechnologiesSMT | 4,703 | – | – | – | – | – | – | 0.00% |
 Fischer Medical VenturesFISCHER | 1,732 | 57.85 | – | +196.0% | +354.6% | 8.3% | 10.2% | 0.20% |
 Tarsons ProductsTARSONS | 1,548 | 139.55 | 2.44 | +10.6% | −59.7% | 1.8% | 1.5% | 0.00% |
 Q-Line BiotechQLINE | 1,196 | 21.47 | – | – | – | 22.6% | – | 0.00% |
 Laxmi DentalLAXMIDENTL | 977 | 31.64 | 4.02 | – | – | 13.7% | 12.0% | 0.00% |
 Hemant Surgical IndustriesHSIL | 834 | 45.84 | – | +117.4% | +126.2% | 18.1% | – | 0.00% |
 Vasa DenticityDENTALKART | 761 | – | 4.37 | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Molbio Diagnostics announcements
Oct 2026
19 Oct · Legal
The exchange asked on 16 Oct 2026
Sep 2026
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 1,320.40 | 1,320.50 | 1,280.00 | 1,302.60 | 1,297.72 | 2,67,969 | 23.9% |
| 28 Oct 2026 | 1,266.00 | 1,341.90 | 1,258.90 | 1,312.70 | 1,310.19 | 7,75,947 | 18.0% |
| 27 Oct 2026 | 1,281.00 | 1,318.50 | 1,253.80 | 1,265.80 | 1,286.11 | 5,67,132 | 19.8% |
| 26 Oct 2026 | 1,244.90 | 1,287.50 | 1,232.60 | 1,273.50 | 1,262.10 | 5,02,488 | 20.9% |
| 23 Oct 2026 | 1,275.00 | 1,304.90 | 1,228.50 | 1,239.10 | 1,259.75 | 13,05,453 | 20.6% |
| 22 Oct 2026 | 1,327.20 | 1,346.30 | 1,252.60 | 1,259.70 | 1,288.66 | 11,36,796 | 19.7% |
| 21 Oct 2026 | 1,463.30 | 1,466.80 | 1,307.80 | 1,322.60 | 1,359.58 | 16,05,700 | 26.8% |
| 19 Oct 2026 | 1,560.00 | 1,570.90 | 1,415.00 | 1,434.80 | 1,471.86 | 14,24,636 | 21.0% |
| 16 Oct 2026 | 1,434.00 | 1,673.70 | 1,424.70 | 1,574.40 | 1,599.36 | 83,24,984 | 8.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- MOLBIO
- BSE code
- 544866
- ISIN
- INE869T01028
- Industry
- Healthcare Equipment & Supplies
- Website
- www.molbiodiagnostics.com
- CIN
- L33125GA2000PLC002909
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2000
- Registered office
- Plot No. L-46, , Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa 403722, Goa
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments